Monopar Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$13.7MTTM through 30 Jun 2026
Free Cash Flow -$12.2MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-11.1%ROE
-12.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio56.04x
Net Debt-$137.5Mnet cash position
Cash & Equivalents$52.8M
Quality Metrics
Altman Z-Score94.10
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPSFY2025: $-1.85
Dividend
No dividend
Capital Allocation
R&D Spend$14.8M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.